Retrospective Analyses of Potential Interventions and Determinants for COVID-19
“OXON leads international collaborative programme to evaluate non-randomised comparative studies of treatments for COVID-19 and prognostic factors”
RWE and RTCs
Randomized Controlled Trials (RCT) provide the most comparable groups at baseline to furnish the most unbiased evidence of treatment effects, although unblinded RCTs may harbour greater post-baseline biases than blinded RCTs.
Carefully conducted non-randomised treatment comparisons with observational cohort designs may also provide reliable evidence of clinical effectiveness and safety of medications similar to those in randomised trials. Non-randomised comparative studies can complement randomised trials with data on patients excluded from randomised trials, uncommon safety events and greater statistical power and more rapid results if retrospective.
A number of studies in COVID-19, and treatments for other conditions, most notably statins, have cast doubt on the reliability of non-randomised comparisons of treatments for, at least short term, clinical effectiveness and safety.
Therefore, we will be conducting real time systematic comparisons of the results of clinical effectiveness and safety of treatments in hospitalised COVID-19 patients from RCTs and non-randomised studies, which will be submitted for publication as well as being posted on this website.